Ca-125 Monitoring during Chemotherapy for Ovarian Cancer

Martoni, Andrea; Bellucco, Antonia; Marabini, A; Orlandi, C; Platé, L.; Bianchi, Davide Gianluca; Pannuti, F

doi:10.1177/172460088600100302

Cited by 10 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation was also significant in patients who did not respond to treatment [13], CA-125 serum levels being increased in all cases of disease pro gression and in 37.5% of the patients with stable disease. In addition, an elevation in CA-125 serum levels was significantly related to cancer relapse.…”

Section: Discussionmentioning

confidence: 58%

Evaluation of the Ovarian Cancer Antigen, CA-125, as a Tumor Marker

Onetto¹,

Bruzzone²,

Conte³

et al. 1989

Oncology

View full text Add to dashboard Cite

The presence of the Ca-125 antigen was tested in the serum of 46 patients with ovarian cancer in order to determine the prognostic value of preoperative levels and its usefulness for monitoring the clinical response in longitudinal studies; survival (S) and progression-free survival (PFS) were also evaluated. In our series, the specificity of the assay in normal subjects and in patients with benign gynecological diseases is 99.3 and 73.2% respectively, and the sensitivity is 91.9%. Preoperative Ca-125 levels are not correlated with S and PFS, whereas an advantage in S and PFS is clearly shown for patients in whom the marker level decreases after treatment. Serial determinations of Ca-125 serum levels provide a reliable test to assess response to therapy and to predict disease progression.

show abstract

Section: Discussionmentioning

confidence: 58%

Evaluation of the Ovarian Cancer Antigen, CA-125, as a Tumor Marker

Onetto¹,

Bruzzone²,

Conte³

et al. 1989

Oncology

View full text Add to dashboard Cite

show abstract

“…(1986) in the presence of small amounts of tumor and precludes the use of CA 125 instead of a second-look operation. Martoni et al (1986) observed that in spite of reduced serum levels, 5/6 patients showed stable disease. In our series also, 113 patients with stable disease showed reduction of CA 125 which did not correlate with tumor regression: it may be that the threshold of 30 % reduction adopted in our study was inadequate to differentiate partial responders from stable-disease patients.…”

Section: Discussionmentioning

confidence: 98%

CA 125 in the monitoring of response to chemotherapy of ovarian carcinoma

Quaranta¹,

Lorusso²,

Coviello³

et al. 1988

Int. J. Cancer

View full text Add to dashboard Cite

CA 125 serum levels were assessed in 23 patients undergoing chemotherapy for advanced epithelial ovarian carcinoma (EOC). Rising, falling and unchanged levels correlated with disease in 21 out of 23 (95%) cases. Ten out of I I patients who showed objective response to chemotherapy had a decrease in antigen levels. Two out of 3 patients with stable disease had unchanged values. Progression was always associated with rising levels. CA 125 is a reliable marker for monitoring response to chemotherapy in advanced epithelial ovarian carcinoma.Although, among solid tumors, EOC is one of the most responsive to cytotoxic chemotherapy, monitoring the response to the treatment has always been difficult. In fact, this tumor often spreads to the peritoneal surface, forming multiple small metastatic nodules that cannot be readily detected by common diagnostic procedures. Moreover, current treatment of EOC provides a surgical debulking as complete as possible, followed by chemotherapy, so that it is often very difficult to assess the effectiveness of a treatment regimen, particularly in patients with small residual burden. Therefore, a second look became a re-staging modality routinely performed for patients achieving complete clinical response as well as for patients with disease otherwise not evaluable (Berek et al., 1984;Schwartz et al., 1980;Webb et al., 1982).Recently, Bast developed a promising assay based on a murine monoclonal antibody (MAb) (OC 125), reacting with the antigen CA 125 which is expressed by more than 80% of non-mucinous EOC (Bast et al., 1981). This marker proved useful in monitoring the response to chemotherapy, in early detection of relapses and in predicting the second-look findings Rubin et al., 1986). The purpose of this study was to verify if serial measurements of CA 125 serum levels correlate with chemotherapy outcome in patients with stage 111-IV advanced ovarian cancer. MATERIAL AND METHODSFrom October 1986 to May 1988 a total of 230 serum samples were collected from 57 patients affected by ovarian cancer. Samples were stored at -20°C until they were analyzed. CA 125 was measured by an MAb (EIA Abbott, North Chicago, IL; CA 125). The reference limit of 35 U/ml as proposed by Bast was verified in 35 control subjects. Only increases or decreases of at least 30 % of the initial value were considered as variations of serum level. Clinical staging was performed according to the system adopted by the International Federation of Gynecology and Obstetrics (IFGO). This series includes 23 patients with stage 111-IV EOC treated with a platinum-containing regimen. All patients had pre-treatment CA 125 level > 35 U/ml. Table I summarizes the characteristics of patients. Serum samples were obtained at the moment of admission to the Oncologic Institute of Bari and before each cycle of chemotherapy. Most patients were referred to us after laparotomy in other hospitals. Therefore we were unable to obtain CA 125 serum levels before laparotomy . Nevertheless, all patients with clinically detectable residual diseas...

show abstract

Pros and cons of gynecologic tumor markers

Bast¹,

Hunter²,

Knapp³

1987

Cancer

View full text Add to dashboard Cite

The use of a tumor marker not only depends upon its sensitivity and specificity, but also upon its ability to influence decisions between alternative plans for patient management. Use of beta human chorionic gonadotropin (hCG) for monitoring gestational trophoblastic neoplasia has set the standard to which other assays must be compared. Beta hCG and alphafetoprotein have provided useful markers for ovarian germ cell tumors. Recently, a monoclonal antibody-based immunoassay for CA 125 antigen has been used to monitor the treatment of epithelial ovarian carcinomas. Persistent elevation of CA 125 in serum has generally reflected persistence of disease at second look surveillance procedures. CA 125 levels can, however, return to within normal limits and residual disease can be found at laparoscopy or laparotomy. CA 125 shows promise for distinguishing benign from malignant pelvic masses. Trials are currently underway to evaluate the potential of CA 125 in combination with other markers to facilitate earlier detection of occult ovarian cancer.

show abstract

Ca-125 Monitoring during Chemotherapy for Ovarian Cancer

Cited by 10 publications

References 3 publications

Evaluation of the Ovarian Cancer Antigen, CA-125, as a Tumor Marker

Evaluation of the Ovarian Cancer Antigen, CA-125, as a Tumor Marker

CA 125 in the monitoring of response to chemotherapy of ovarian carcinoma

Pros and cons of gynecologic tumor markers

Contact Info

Product

Resources

About